George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
|Articles|September 16, 2008
- July15 2004
- Volume 11
- Issue 13
Wall Street Peek
Author(s)Michael Sheehan
Advertisement
Wall Street Words: An A to ZGuide to Investment Terms for Today'sInvestor
When is a no-load fund not a noloadfund? According to David L. Scott,author of ($13.95; Houghton Mifflin;2003), when you buy a no-load fundthrough a third party, the fund mayjack up its annual fees to cover anyincentive payments it makes to the broker.The higher fees cut into returnsover the long term, which is why you'rebetter off looking for true no-loadfunds that are sold directly to investors.Scott deals out some more market wisdomalong with the easy-to-understanddefinitions of terms like exchange-tradedfunds, pro forma earnings, and decimalization.There's also a list of investmentWeb sites, along with charts, casestudies, and investment tips.
Articles in this issue
about 18 years ago
Batten Down Your Inheritance Hatchesabout 18 years ago
Decide What to Do with Your IRA Assetsabout 18 years ago
Start Your Retirement Plan Immediatelyabout 18 years ago
Know when Less Is More and More Is Lessabout 18 years ago
Ease Worries of the Sandwich Generationabout 18 years ago
Uncover the Fine Print on Annuitiesabout 18 years ago
Impart Memories Before They Are Goneabout 18 years ago
Rent Real Estate as an Investment Optionabout 18 years ago
Find the Right Mortgage Lender for Youabout 18 years ago
Renovate Without Building Property TaxAdvertisement
Related to this article
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
2
FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B
3
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5